- Exchange: Natl India
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Generic Pharmaceuticals
Ranbaxy Laboratories Ltd
+ Add to WatchlistRBXY:IN
351.80 INR 1.00 0.28%As of 23:54:01 ET on 06/18/2013.
Snapshot for Ranbaxy Laboratories Ltd (RBXY)
| Open: | 350.25 | Day's Range: | 348.70 - 352.90 | Volume: | 154,735 |
|---|---|---|---|---|---|
| Previous Close: | 352.80 | 52wk Range: | 342.75 - 578.40 | 1-Yr Rtn: | -26.72% |
Key Statistics for RBXY
| Current P/E Ratio (ttm) | 16.1328 |
|---|---|
| Estimated P/E(12/2013) | 14.5131 |
| Relative P/E vs. SENSEX | 1.0515 |
| Earnings Per Share (INR) (ttm) | 21.8685 |
| Est. EPS (INR) (12/2013) | 24.3090 |
| Est. PEG Ratio | 0.2057 |
| Market Cap (M INR) | 149,270.02 |
| Shares Outstanding (M) | 423.10 |
| 30 Day Average Volume | 1,641,996 |
| Price/Book (mrq) | 3.6583 |
| Price/Sale (ttm) | 1.2167 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend (INR) | 2.0000 |
| Last Dividend | 04/28/2011 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for RBXY
Company Profile & Key Executives for RBXY
Ranbaxy Laboratories Limited manufactures and distributes a wide range of pharmaceutical products. The Company makes multisource antibiotics, analgesics, anti-inflammatory drugs and anti-ulcerant/gastrointestinal drugs such as "Roscillin" (Ampicillin), "Cifran" (Ciprofloxacin) and "Sporidex" (Cephalexin).
| Tsutomu UneChairman | Arun SawhneyCEO/Managing Director |
| Indrajit BanerjeePresident/CFO | Sudershan K AroraPres:Research & Dev |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
RBXY News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page